<DOC>
	<DOCNO>NCT02179099</DOCNO>
	<brief_summary>This single arm pilot study evaluate feasibility preliminary safety single intravesical instillation TC-3 gel mixed botulinum toxin ( BTX ) symptomatic improvement overactive bladder patient .</brief_summary>
	<brief_title>Safety Efficacy Intravesical Botulinum Toxin TC-3 Gel OAB Patients</brief_title>
	<detailed_description>BTX consider therapeutic option overactive bladder ( OAB ) . Randomized placebo-controlled study show BTX administer intramural injection bladder wall patient OAB lead significant improvement urodynamic parameter quality life . ( Schurch 2008 ) . On hand , animal study suggest intravesically apply BTX act decrease frequency bladder contraction inhibit sensory mechanism urothelium rather directly inhibition smooth muscle contraction . ( Khera 2005 ) . The efficacy intravesical BTX instillation test open label trial overactive bladder patient whereby clinical improvement observe short-lasting mean duration 6.8 week ( Petrou 2009 , Krhut 2011 ) . The short exposure duration urothelium BTX could one factor responsible lack sustained effect . TC-3 hydrogel reverse thermal gelation property mixed BTX instill intravesically serves drug reservoir allow gradual release BTX thereby extend contact bladder urothelium .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Female 18 85 year old symptom idiopathic OAB ≥ 3 month prior screen . Patient sign Informed Consent Form willing able comply requirement protocol , include proper completion void diary selfadministered questionnaire . Patient nonresponder anticholinergic betaagonist drug therapy compliant treatment due intolerable side effect . Patient urination frequency least 8 micturition per 24 hour . Patients least 3 urinary urgency incontinence ( UUI ) episodes per 3day bladder diary , 1 incontinencefree day . Patients PVR ≤100 ml . Patient single PVR &gt; 100 ml follow two consecutive PVR measurement &lt; 100 ml may include study ) . If patient female childbearing potential , negative urine pregnancy test screen visit practice reliable method contraception throughout study , 6 month post treatment . Patient mentally competent ability understand comply requirement study . Patient active urinary tract infection confirm urine culture . In case UTI proven urine culture , patient treat full course antibiotic , instillation postpone 1 week follow negative urine culture demonstration . Pregnant ( positive urine pregnancy test ) , plan become pregnant study period , breastfeeding , childbearing potential practicing reliable contraception** . Patient clinically significant Bladder Outlet Obstruction ( BOO ) . Patient neurogenic bladder . Patient currently use Clean Intermittent Catheterization ( CIC ) . Patient document unstable diabetes without diabetic neuropathy . Patient currently undergo biofeedback , pelvic muscle rehabilitation , pelvic floor physical therapy , electricalstimulation . Patient 24hour total urine volume void great 3,000 ml measure screening period . Patient vesicoureteral reflux , interstitial cystitis , genitourinary fistula Patient pelvic organ prolapse stage III IV , ( i.e . distal part prolapse protrude 1 cm beyond hymen strain ) Patient low tract genitourinary malignancy Patient prior antiincontinence surgery intervention include midurethral sling , Burch bladder suspension , sacral neuromodulation , tibial nerve stimulation . Patient prior Botox antiincontinence therapy . Patient previous pelvic radiation therapy Patient morbidly obese ( BMI &gt; 40 Kg/m2 ) . Patient treat 2 UTIs within last 6 month . Patient immunomodulatory therapy ( suppressive stimulatory ) Patient participate prior clinical trial BTX+TC3 gel Patient current major psychiatric disorder psychiatric medical issue would interfere study participation ( e.g . dementia , psychosis , upcoming major surgery , etc ) . Subject severe cardiac , pulmonary , renal , hepatic disease judgment study physician would preclude participation study . Patient life expectancy le 12 month .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>OAB</keyword>
	<keyword>urgency</keyword>
	<keyword>botulinum toxin</keyword>
	<keyword>BTX</keyword>
	<keyword>botox</keyword>
	<keyword>intravesical</keyword>
	<keyword>TheraCoat</keyword>
	<keyword>TCGel</keyword>
	<keyword>TC-3 Gel</keyword>
</DOC>